Lymphokine-activated killer cells, natural killer cells and cytokines.
暂无分享,去创建一个
[1] G. Trinchieri,et al. Production of hematopoietic colony-stimulating factors by human natural killer cells , 1989, The Journal of experimental medicine.
[2] E. Unanue,et al. Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. , 1989, Journal of immunology.
[3] U. Dianzani,et al. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine‐activated killer cell precursors , 1989, European journal of immunology.
[4] Craig W. Reynolds,et al. The proliferation and life‐span of rat large granular lymphocytes: effects of cytokines , 1989, European journal of immunology.
[5] T. Honjo,et al. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity , 1989, The Journal of experimental medicine.
[6] J. Banchereau,et al. Tumor necrosis factor-alpha strongly potentiates interleukin-3 and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34+ hematopoietic progenitor cells. , 1990 .
[7] H. Masutani,et al. Mitogenicity and down-regulation of high-affinity interleukin 2 receptor by YTA-1 and YTA-2, monoclonal antibodies that recognize 75-kDa molecules on human large granular lymphocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Thompson,et al. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. , 1989, Cancer research.
[9] M. Bennett,et al. Resistance to Mycoplasma pulmonis mediated by activated natural killer cells. , 1990, The Journal of infectious diseases.
[10] J. Ortaldo,et al. Mechanisms of target cell killing by natural killer cells. , 1989, Current opinion in immunology.
[11] K. Sugamura,et al. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL- 2 binding , 1990, The Journal of experimental medicine.
[12] L. Lanier,et al. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.
[13] M. V. D. van den Brink,et al. The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures , 1990, The Journal of experimental medicine.
[14] E. Hersh,et al. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. , 1989, Journal of immunology.
[15] C. Figdor,et al. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. , 1988, Journal of immunology.
[16] H. Young,et al. Interleukin 2-induced proliferation of murine natural killer cells in vivo , 1990, The Journal of experimental medicine.
[17] G. Trinchieri,et al. Biology of Natural Killer Cells , 1989, Advances in Immunology.
[18] F. Podlaski,et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[19] S. Ferrini,et al. Immunotherapy and immunity to cancer: cellular mechanisms. , 1989, Current opinion in immunology.
[20] J. Xiao,et al. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells. , 1989, Cellular immunology.
[21] E. A. Havell. Evidence that tumor necrosis factor has an important role in antibacterial resistance. , 1989, Journal of immunology.
[22] C. Biron,et al. Cyclosporin A inhibition of interleukin 2 gene expression, but not natural killer cell proliferation, after interferon induction in vivo , 1990, The Journal of experimental medicine.
[23] J. Blay,et al. Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation. , 1990, The Journal of clinical investigation.
[24] G. Trinchieri,et al. Inactivation of natural killer cell cytotoxic activity after interaction with target cells. , 1981, Journal of immunology.
[25] J. D. Young. Killing of target cells by lymphocytes: a mechanistic view. , 1989, Physiological reviews.
[26] D. Yuan,et al. Regulation of B lymphocytes by natural killer cells. Role of IFN-gamma. , 1989, Journal of immunology.
[27] G. Trinchieri,et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.
[28] G. Trinchieri,et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers , 1991, The Journal of experimental medicine.
[29] T. Miyawaki,et al. Interleukin 3 enhanced interleukin 2-dependent maturation of NK progenitor cells in bone marrow from mice with severe combined immunodeficiency. , 1989, Cellular immunology.
[30] M. Caligiuri,et al. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[31] G. Trinchieri,et al. Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon , 1985, The Journal of experimental medicine.
[32] G. Bosma,et al. Transplantable progenitors of natural killer cells are distinct from those of T and B lymphocytes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[33] G. Trinchieri,et al. Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activity , 1985, The Journal of experimental medicine.
[34] G. Trinchieri,et al. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells , 1988, The Journal of experimental medicine.
[35] G. Trinchieri,et al. Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes , 1989, The Journal of experimental medicine.
[36] L. Lanier,et al. Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.
[37] G. Trinchieri,et al. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. , 1986, Journal of immunology.
[38] L. Lanier,et al. Natural killer cells: definition of a cell type rather than a function. , 1986, Journal of immunology.
[39] B. Kwon,et al. Induction of perforin and serine esterases in a murine cytotoxic T lymphocyte clone. , 1990, Journal of immunology.
[40] M. V. D. van den Brink,et al. Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells. , 1989, Cellular immunology.
[41] T. Luger,et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. , 1989, Journal of immunology.
[42] Masakazu,et al. Expansion of natural killer cells but not T cells in human interleukin 2/interleukin 2 receptor (Tac) transgenic mice , 1989, The Journal of experimental medicine.
[43] G. Trinchieri,et al. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. , 1987, Natural immunity and cell growth regulation.
[44] F. Malavasi,et al. Ultrastructural analysis of human natural killer cell activation. , 1987, Blood.
[45] K. Sugamura,et al. Activation of natural killer cells via the p75 interleukin 2 receptor , 1989, The Journal of experimental medicine.